These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35266882)

  • 1. Non calcium phosphate binders - Is there any evidence of benefit.
    Jadav PR; Husain SA; Mohan S; Crew R
    Curr Opin Nephrol Hypertens; 2022 May; 31(3):288-296. PubMed ID: 35266882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. State-of-the-Art Management of Hyperphosphatemia in Patients With CKD: An NKF-KDOQI Controversies Perspective.
    Scialla JJ; Kendrick J; Uribarri J; Kovesdy CP; Gutiérrez OM; Jimenez EY; Kramer HJ
    Am J Kidney Dis; 2021 Jan; 77(1):132-141. PubMed ID: 32771650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of phosphate binders in chronic kidney disease.
    Ketteler M; Biggar PH
    Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):413-20. PubMed ID: 23736841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
    Patel L; Bernard LM; Elder GJ
    Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in pharmacotherapy for hyperphosphatemia in renal disease.
    Spasovski G
    Expert Opin Pharmacother; 2015; 16(17):2589-99. PubMed ID: 26374200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal use of phosphate binders in chronic kidney disease.
    Sonikian M; Papachristou E; Goumenos DS
    Expert Opin Pharmacother; 2013 Dec; 14(18):2521-32. PubMed ID: 24215605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?
    St. Peter WL; Wazny LD; Weinhandl E; Cardone KE; Hudson JQ
    Drugs; 2017 Jul; 77(11):1155-1186. PubMed ID: 28584909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles.
    Locatelli F; Del Vecchio L; Violo L; Pontoriero G
    Expert Opin Drug Saf; 2014 May; 13(5):551-61. PubMed ID: 24702470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphate binders in chronic kidney disease: an updated narrative review of recent data.
    Floege J
    J Nephrol; 2020 Jun; 33(3):497-508. PubMed ID: 31865608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
    Molony DA; Stephens BW
    Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initiation of Sevelamer and Mortality among Hemodialysis Patients Treated with Calcium-Based Phosphate Binders.
    Komaba H; Wang M; Taniguchi M; Yamamoto S; Nomura T; Schaubel DE; Smith AR; Zee J; Karaboyas A; Bieber B; Fukagawa M; Tentori F
    Clin J Am Soc Nephrol; 2017 Sep; 12(9):1489-1497. PubMed ID: 28724618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic Review and Meta-Analyses of the Effects of Phosphate-Lowering Agents in Nondialysis CKD.
    Lioufas NM; Pascoe EM; Hawley CM; Elder GJ; Badve SV; Block GA; Johnson DW; Toussaint ND
    J Am Soc Nephrol; 2022 Jan; 33(1):59-76. PubMed ID: 34645696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
    Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
    Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Ruospo M; Palmer SC; Natale P; Craig JC; Vecchio M; Elder GJ; Strippoli GF
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006023. PubMed ID: 30132304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update on phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a review of safety profiles.
    Ogata H; Takeshima A; Ito H
    Expert Opin Drug Saf; 2022 Jul; 21(7):947-955. PubMed ID: 35180026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Phosphate binders : What are the recent evidences ?].
    Bouajila IA; Martin PY; De Seigneux S
    Rev Med Suisse; 2017 Feb; 13(551):468-472. PubMed ID: 28714648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and potential treatment options for hyperphosphatemia.
    Carfagna F; Del Vecchio L; Pontoriero G; Locatelli F
    Expert Opin Drug Saf; 2018 Jun; 17(6):597-607. PubMed ID: 29783873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis.
    Habbous S; Przech S; Acedillo R; Sarma S; Garg AX; Martin J
    Nephrol Dial Transplant; 2017 Jan; 32(1):111-125. PubMed ID: 27651467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of calcium and non calcium-based phosphate binders in chronic kidney disease.
    Elder GJ; Center J
    Nephrology (Carlton); 2017 Mar; 22 Suppl 2():42-46. PubMed ID: 28429551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Next-generation phosphate binders: focus on iron-based binders.
    Nastou D; Fernández-Fernández B; Elewa U; González-Espinoza L; González-Parra E; Sanchez-Niño MD; Ortiz A
    Drugs; 2014 Jun; 74(8):863-77. PubMed ID: 24848754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.